Stay updated with breaking news from சாம் லாய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck and Ridgeback's molnupiravir rollout difficult to map in uncertain Covid-19 landscape pharmaceutical-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-technology.com Daily Mail and Mail on Sunday newspapers.
Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Inhalon Biopharma, a start-up immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating a variety of acute. ....
by WRAL TechWire May 26, 2021 . DURHAM –Inhalon Biopharma is developing a “muco-trapping” antibody platform that could be used to treat acute respiratory infections, including COVID-19, and the Durham-based startup has now been awarded a $7 million contract by the United States Army Medical Research & Development Command (USAMRDC). The contract will allow the company to conduct a placebo-controlled Phase 1 and Phase 2a study of its technology in COVID-19 outpatients, the company shared in a statement. The technology, currently designated IN-006, is described by the company as a potent, neutralizing monoclonal antibody that is being investigated as a possible treatment for COVID-19. The company expects results of the study in 2022. ....
Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled "Muco-trapping" Antibody for the Treatment of COVID-19 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.